2019/8/20 – CRI Report https://www.cri-report.com market research vender! Fri, 05 Nov 2021 04:37:06 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg 2019/8/20 – CRI Report https://www.cri-report.com 32 32 Global Corporate Wellness Market (2018-2023) https://www.cri-report.com/global-corporate-wellness-market-2018-2023/ https://www.cri-report.com/global-corporate-wellness-market-2018-2023/#respond Sat, 12 Sep 2020 05:17:36 +0000 https://www.cri-report.com/product/global-corporate-wellness-market-2018-2023/ The corporate wellness market, which comprises the health risk assessment, stress management, fitness and weight management segments, is expected to witness steady growth due to increasing cognizance of workforce wellness. An increase in the prevalence of lifestyle related diseases among employees, owing to hectic work, long hours, and unhealthy eating habits, creates a huge demand for corporate wellness programs across the world. The global corporate wellness market is forecast to expand at a CAGR of 4.95%, and will reach a value of USD 61.95 Bn by 2023, from USD 48.66…

The post Global Corporate Wellness Market (2018-2023) first appeared on CRI Report.

]]> The corporate wellness market, which comprises the health risk assessment, stress management, fitness and weight management segments, is expected to witness steady growth due to increasing cognizance of workforce wellness. An increase in the prevalence of lifestyle related diseases among employees, owing to hectic work, long hours, and unhealthy eating habits, creates a huge demand for corporate wellness programs across the world. The global corporate wellness market is forecast to expand at a CAGR of 4.95%, and will reach a value of USD 61.95 Bn by 2023, from USD 48.66 Bn in 2018.
Segmentation based on service type
Based on the service type, the health risk assessment segment held the highest market share (46.56%) in 2018, owing to an increase in the incidence of chronic diseases, improved awareness among employers to keep their employees healthy, and higher spending on healthcare by employers. It was followed by the stress management segment with a share of 28.57% in 2018. This was on account of higher stress, anxiety, and depression among employees.

The global health risk assessment market is forecast to expand at a CAGR of 4.52%, and will reach USD 28.26 Bn by 2023, from USD 22.66 Bn in 2018. The higher adoption of employee’s health screening is aimed at promoting healthy lifestyles and reducing health risks among employees.

Segmentation based on end user
Based on end user, the market is segmented into large-scale, medium-scale and small-scale organizations. Large-scale organizations held the highest market share (42.1%) in 2018, and will continue to expand at a CAGR of 3.99% during the 2018-2023 period, owing to the adoption of new technologies, and increasing expenditure on employees’ well-being.

Regional insights
The corporate wellness market in North America accounted for the highest market share (37.42%) in 2018, and will expand at a CAGR of 4.98% during the 2018-2023 period, owing to factors like high occurrence of lifestyle associated diseases, adoption of premium wellness services and programs, and favorable government policies.

In 2018, the health risk assessment segment contributed the highest revenue (USD 8.74 Bn) in the North America region, owing to increasing obesity, consumption of unhealthy food, and lack of physical activity among employees. This segment is projected to expand at a CAGR of 4.91% during the 2018-2023 period. The stress management segment is expected to hold a market share 26.9% by 2023, expanding at a CAGR of 3.35% during the 2018-2023 period. In the U.S., employers lose approximately 225 Mn working days annually due to stress, resulting in reduced productivity. This is likely to aid the growth of the stress management market in the region. The fitness and weight management segment is anticipated to witness the highest growth rate (7.05%) during the forecast period, owing to increasing awareness about nutrition and healthy lifestyles, and an expanding number of fitness centers in this region.

The U.S. dominated the regional corporate wellness market due to a steady rise in investments, adoption of corporate wellness services, escalating healthcare costs, and the rising incidence of chronic diseases. Furthermore, the U.S. market is being driven by higher adoption of newly introduced corporate wellness plans for fitness, weight management, and nutrition.

Companies covered
Virgin Pulse
ComPsych Corporation
Vitality
Quest Diagnostics Health & Wellness
Interactive Health
BurnAlong
FitBliss
IncentFit
Training Amigo

The post Global Corporate Wellness Market (2018-2023) first appeared on CRI Report.

]]> https://www.cri-report.com/global-corporate-wellness-market-2018-2023/feed/ 0 Investigation Report on China’s Basiliximab Market, 2019-2023 https://www.cri-report.com/investigation-report-on-chinas-basiliximab-market-2019-2023/ Tue, 20 Aug 2019 01:18:02 +0000 https://www.cri-report.com/product/import-placeholder-for-1908402/ Description Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen. As fibrin is an important composition of thrombus, current thrombolytic therapy mainly use drugs such as Streptokinase, Urokinase and Tissue Plasminogen Activator (t-PA) to dissolve fibrin. Thrombolytic drugs include three generations. The first generation is non-specific plasminogen activators such as Streptokinase and Urokinase; the second generation is represented by t-PA such as Alteplase and Prourokinase; the third generation includes Reteplase, Tenecteplase, Nateplase, Recombinant…

The post Investigation Report on China’s Basiliximab Market, 2019-2023 first appeared on CRI Report.

]]> Description
Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen. As fibrin is an important composition of thrombus, current thrombolytic therapy mainly use drugs such as Streptokinase, Urokinase and Tissue Plasminogen Activator (t-PA) to dissolve fibrin.
Thrombolytic drugs include three generations. The first generation is non-specific plasminogen activators such as Streptokinase and Urokinase; the second generation is represented by t-PA such as Alteplase and Prourokinase; the third generation includes Reteplase, Tenecteplase, Nateplase, Recombinant Human Urokinase, etc.
Although Urokinase is a thrombolytic drug of the first generation, it is widely used in China. It is an enzyme protein isolated from healthy human urine or cultured from human kidney tissue.
Urokinase acts directly on the endogenous fibrinolytic system. It can catalyze the cracking of plasminogen to plasmin which dissolves thrombi by degrading fibrin clots as well as the fibrinogen, coagulation factors V and VIII in blood circulation. With a rapid onset and good effect on newly formed thrombi, Urokinase can also increase the vascular enzymatic activity of adenosine diphosphate (ADP), inhibit ADP-induced platelet aggregation and prevent thrombosis. After intravenous infusion, the activity of plasmin in the patient will be significantly increased; after a few hours of drug withdrawal, the activity of plasmin will be restored. As a traditional thrombolytic drug that has been marketed in China for many areas, Urokinase is widely used to treat acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombosis, lower extremity vein thrombosis and other forms of vascular thrombosis.
Economic development, aging population and unhealthy diet push up the incidence of thrombotic diseases in China, which boosts the demand for Urokinase. According to CRI’s market survey, in 2017, the sales value of Urokinase in China reached CNY 50.56 million, representing a CAGR of 7.90% from 2013 to 2017. The Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd. took up the largest market share in China. Its market share was about 50.60% by sales value and about 38.50% by sales volume.
It is expected that the market size of Urokinase in China will continue to grow in the next few years.

Topics covered:
– Market size of Urokinase in China
– Competitive landscape of China’s Urokinase market
– Prices of Urokinase in China
– Favorable and unfavorable factors influencing China’s Urokinase market
– Prospect of China’s Urokinase market

The post Investigation Report on China’s Basiliximab Market, 2019-2023 first appeared on CRI Report.

]]> Investigation Report on China’s Diclofenac Market, 2019-2023 https://www.cri-report.com/investigation-report-chinas-diclofenac-market/ Tue, 20 Aug 2019 01:18:01 +0000 https://www.cri-report.com/product/import-placeholder-for-1908401/ According to CRI's market survey,  China Diclofenac Market size was about CNY 103 million in 2017, slightly lower than that in 2016.

The post Investigation Report on China’s Diclofenac Market, 2019-2023 first appeared on CRI Report.

]]> According to CRI’s market survey,  China Diclofenac Market size was about CNY 103 million in 2017, slightly lower than that in 2016.

China’s Diclofenac Market

Rheumatoid arthritis is a common frequently-occurring disease. According to the 2018 Chinese Guideline for the Diagnosis and Treatment of Rheumatoid Arthritis, in 2018, a total of 5 million people in China had rheumatoid arthritis.

As an autoimmune disease, rheumatoid arthritis not only leads to common symptoms of rheumatism such as synovitis and arthralgia but also causes problems with skin and eyes. Its complications also include lung diseases, cardiovascular and cerebrovascular diseases and malignant tumors. As the disease progresses, the incidence of complications will gradually increase, and the disability rate will also rise.

When the disease lasts one to five years, the disability rate is lower than 20%; when it lasts for more than 15 years, the disability rate is higher than 60%.
Non-steroidal anti-inflammatory drugs (NSAIDs) such as Diclofenac can be used to alleviate the pain, swelling and stiffness caused by rheumatoid arthritis.

The mechanism of Diclofenac action is to selectively cleave the action of cyclooxygenase in arachidonic acid metabolism series, block the synthesis of prostaglandin E2 (PGE2) and inhibit mutagenicity and the effect of pain. Diclofenac is a phenylacetic acid drug that has remarkable anti-rheumatic, anti-inflammatory, analgesic and antipyretic effects.

The indications for different dosage forms of Diclofenac are different. For example, Diclofenac tablets and injections are clinically used to treat rheumatic and rheumatoid arthritis, ankylosing spondylitis, osteoarthrosis, moderate pain such as postoperative and post-traumatic pain and acute musculoskeletal diseases, and fever caused by inflammations.

Diclofenac eye drops are used to prevent miosis in and treat inflammations after cataract extraction, treat non-infectious eye inflammations caused or not caused by surgeries, prevent postoperative inflammatory reactions and the formation of cystoid macular edema, promote the formation of filtration blebs after glaucoma filtering surgeries, and treat allergic conjunctivitis.

Starting from the 1970s, Swiss company Ciba-Geigy, SS Pharmaceutical and Wakamoto Pharmaceutical Co., Ltd. successively developed and launched Diclofenac products. After years of clinical application, Diclofenac remains an important product of Novartis. In 1993, it was introduced to China as a non-selective NSAID commonly seen in clinical application.

Diclofenac takes up a large share of China’s NSAID market in the dosage forms of tablets, capsules, injections, externally used gels, compound preparations, etc. Oral Diclofenac accounts for a large proportion. Since Diclofenac is a general drug, there are more than 100 Diclofenac manufacturers in China. Foreign brands Voltaren, Difene and Diclac take up 75% of the market while domestic brands only take up 25%.

According to CRI’s market survey, the sales value of Diclofenac in China was about CNY 103 million in 2017, slightly lower than that in 2016. In 2017, Beijing Novartis Pharma Co., Ltd. ranked the first on China’s Diclofenac market, with market share by sales value reaching 45.30% and market share by sales volume reaching 35.20%.

The other major market players were Shenyang Xingqi Pharmaceutical Co., Ltd., Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd., KlingePharma and Fujisawa.

CRI expects that, with the increasing number of patients with rheumatoid arthritis and other indications for Diclofenac, China’s Diclofenac market still has certain development potential.

 

Topics covered:
– Incidence of rheumatoid arthritis in China
– Supply of and demand for Diclofenac in China
– Retail prices of Diclofenac in China
– Major factors influencing China’s Diclofenac market
– Prospect of China’s Diclofenac market from 2019 to 2023

Investigation Report on China’s Golimumab Market 2021-2025

The post Investigation Report on China’s Diclofenac Market, 2019-2023 first appeared on CRI Report.

]]> Investigation Report on China’s Polyene Phosphatidylcholine Market, 2019-2023 https://www.cri-report.com/investigation-report-on-chinas-polyene-phosphatidylcholine-market-2019-2023/ Tue, 20 Aug 2019 01:17:55 +0000 https://www.cri-report.com/product/import-placeholder-for-1908400/ Description Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen. As fibrin is an important composition of thrombus, current thrombolytic therapy mainly use drugs such as Streptokinase, Urokinase and Tissue Plasminogen Activator (t-PA) to dissolve fibrin. Thrombolytic drugs include three generations. The first generation is non-specific plasminogen activators such as Streptokinase and Urokinase; the second generation is represented by t-PA such as Alteplase and Prourokinase; the third generation includes Reteplase, Tenecteplase, Nateplase, Recombinant…

The post Investigation Report on China’s Polyene Phosphatidylcholine Market, 2019-2023 first appeared on CRI Report.

]]> Description
Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen. As fibrin is an important composition of thrombus, current thrombolytic therapy mainly use drugs such as Streptokinase, Urokinase and Tissue Plasminogen Activator (t-PA) to dissolve fibrin.
Thrombolytic drugs include three generations. The first generation is non-specific plasminogen activators such as Streptokinase and Urokinase; the second generation is represented by t-PA such as Alteplase and Prourokinase; the third generation includes Reteplase, Tenecteplase, Nateplase, Recombinant Human Urokinase, etc.
Although Urokinase is a thrombolytic drug of the first generation, it is widely used in China. It is an enzyme protein isolated from healthy human urine or cultured from human kidney tissue.
Urokinase acts directly on the endogenous fibrinolytic system. It can catalyze the cracking of plasminogen to plasmin which dissolves thrombi by degrading fibrin clots as well as the fibrinogen, coagulation factors V and VIII in blood circulation. With a rapid onset and good effect on newly formed thrombi, Urokinase can also increase the vascular enzymatic activity of adenosine diphosphate (ADP), inhibit ADP-induced platelet aggregation and prevent thrombosis. After intravenous infusion, the activity of plasmin in the patient will be significantly increased; after a few hours of drug withdrawal, the activity of plasmin will be restored. As a traditional thrombolytic drug that has been marketed in China for many areas, Urokinase is widely used to treat acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombosis, lower extremity vein thrombosis and other forms of vascular thrombosis.
Economic development, aging population and unhealthy diet push up the incidence of thrombotic diseases in China, which boosts the demand for Urokinase. According to CRI’s market survey, in 2017, the sales value of Urokinase in China reached CNY 50.56 million, representing a CAGR of 7.90% from 2013 to 2017. The Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd. took up the largest market share in China. Its market share was about 50.60% by sales value and about 38.50% by sales volume.
It is expected that the market size of Urokinase in China will continue to grow in the next few years.

Topics covered:
– Market size of Urokinase in China
– Competitive landscape of China’s Urokinase market
– Prices of Urokinase in China
– Favorable and unfavorable factors influencing China’s Urokinase market
– Prospect of China’s Urokinase market

The post Investigation Report on China’s Polyene Phosphatidylcholine Market, 2019-2023 first appeared on CRI Report.

]]> Investigation Report on China’s Recombinant Human Endostatin Market, 2019-2023 https://www.cri-report.com/investigation-report-on-chinas-recombinant-human-endostatin-market-2019-2023/ Tue, 20 Aug 2019 01:17:48 +0000 https://www.cri-report.com/product/import-placeholder-for-1908398/ Description Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen. As fibrin is an important composition of thrombus, current thrombolytic therapy mainly use drugs such as Streptokinase, Urokinase and Tissue Plasminogen Activator (t-PA) to dissolve fibrin. Thrombolytic drugs include three generations. The first generation is non-specific plasminogen activators such as Streptokinase and Urokinase; the second generation is represented by t-PA such as Alteplase and Prourokinase; the third generation includes Reteplase, Tenecteplase, Nateplase, Recombinant…

The post Investigation Report on China’s Recombinant Human Endostatin Market, 2019-2023 first appeared on CRI Report.

]]> Description
Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen. As fibrin is an important composition of thrombus, current thrombolytic therapy mainly use drugs such as Streptokinase, Urokinase and Tissue Plasminogen Activator (t-PA) to dissolve fibrin.
Thrombolytic drugs include three generations. The first generation is non-specific plasminogen activators such as Streptokinase and Urokinase; the second generation is represented by t-PA such as Alteplase and Prourokinase; the third generation includes Reteplase, Tenecteplase, Nateplase, Recombinant Human Urokinase, etc.
Although Urokinase is a thrombolytic drug of the first generation, it is widely used in China. It is an enzyme protein isolated from healthy human urine or cultured from human kidney tissue.
Urokinase acts directly on the endogenous fibrinolytic system. It can catalyze the cracking of plasminogen to plasmin which dissolves thrombi by degrading fibrin clots as well as the fibrinogen, coagulation factors V and VIII in blood circulation. With a rapid onset and good effect on newly formed thrombi, Urokinase can also increase the vascular enzymatic activity of adenosine diphosphate (ADP), inhibit ADP-induced platelet aggregation and prevent thrombosis. After intravenous infusion, the activity of plasmin in the patient will be significantly increased; after a few hours of drug withdrawal, the activity of plasmin will be restored. As a traditional thrombolytic drug that has been marketed in China for many areas, Urokinase is widely used to treat acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombosis, lower extremity vein thrombosis and other forms of vascular thrombosis.
Economic development, aging population and unhealthy diet push up the incidence of thrombotic diseases in China, which boosts the demand for Urokinase. According to CRI’s market survey, in 2017, the sales value of Urokinase in China reached CNY 50.56 million, representing a CAGR of 7.90% from 2013 to 2017. The Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd. took up the largest market share in China. Its market share was about 50.60% by sales value and about 38.50% by sales volume.
It is expected that the market size of Urokinase in China will continue to grow in the next few years.

Topics covered:
– Market size of Urokinase in China
– Competitive landscape of China’s Urokinase market
– Prices of Urokinase in China
– Favorable and unfavorable factors influencing China’s Urokinase market
– Prospect of China’s Urokinase market

The post Investigation Report on China’s Recombinant Human Endostatin Market, 2019-2023 first appeared on CRI Report.

]]> Investigation Report on China’s Urokinase Market, 2019-2023 https://www.cri-report.com/investigation-report-on-chinas-urokinase-market-2019-2023/ Tue, 20 Aug 2019 01:17:46 +0000 https://www.cri-report.com/product/import-placeholder-for-1908397/ Description Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen. As fibrin is an important composition of thrombus, current thrombolytic therapy mainly use drugs such as Streptokinase, Urokinase and Tissue Plasminogen Activator (t-PA) to dissolve fibrin. Thrombolytic drugs include three generations. The first generation is non-specific plasminogen activators such as Streptokinase and Urokinase; the second generation is represented by t-PA such as Alteplase and Prourokinase; the third generation includes Reteplase, Tenecteplase, Nateplase, Recombinant…

The post Investigation Report on China’s Urokinase Market, 2019-2023 first appeared on CRI Report.

]]> Description
Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen. As fibrin is an important composition of thrombus, current thrombolytic therapy mainly use drugs such as Streptokinase, Urokinase and Tissue Plasminogen Activator (t-PA) to dissolve fibrin.
Thrombolytic drugs include three generations. The first generation is non-specific plasminogen activators such as Streptokinase and Urokinase; the second generation is represented by t-PA such as Alteplase and Prourokinase; the third generation includes Reteplase, Tenecteplase, Nateplase, Recombinant Human Urokinase, etc.
Although Urokinase is a thrombolytic drug of the first generation, it is widely used in China. It is an enzyme protein isolated from healthy human urine or cultured from human kidney tissue.
Urokinase acts directly on the endogenous fibrinolytic system. It can catalyze the cracking of plasminogen to plasmin which dissolves thrombi by degrading fibrin clots as well as the fibrinogen, coagulation factors V and VIII in blood circulation. With a rapid onset and good effect on newly formed thrombi, Urokinase can also increase the vascular enzymatic activity of adenosine diphosphate (ADP), inhibit ADP-induced platelet aggregation and prevent thrombosis. After intravenous infusion, the activity of plasmin in the patient will be significantly increased; after a few hours of drug withdrawal, the activity of plasmin will be restored. As a traditional thrombolytic drug that has been marketed in China for many areas, Urokinase is widely used to treat acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombosis, lower extremity vein thrombosis and other forms of vascular thrombosis.
Economic development, aging population and unhealthy diet push up the incidence of thrombotic diseases in China, which boosts the demand for Urokinase. According to CRI’s market survey, in 2017, the sales value of Urokinase in China reached CNY 50.56 million, representing a CAGR of 7.90% from 2013 to 2017. The Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd. took up the largest market share in China. Its market share was about 50.60% by sales value and about 38.50% by sales volume.
It is expected that the market size of Urokinase in China will continue to grow in the next few years.

Topics covered:
– Market size of Urokinase in China
– Competitive landscape of China’s Urokinase market
– Prices of Urokinase in China
– Favorable and unfavorable factors influencing China’s Urokinase market
– Prospect of China’s Urokinase market

The post Investigation Report on China’s Urokinase Market, 2019-2023 first appeared on CRI Report.

]]> Research Report on Global and China’s Automotive Radiator Industries, 2019-2023 https://www.cri-report.com/research-report-on-global-and-chinas-automotive-radiator-industries-2019-2023/ Tue, 20 Aug 2019 01:17:42 +0000 https://www.cri-report.com/product/import-placeholder-for-1908396/ Description The automotive radiator is one of the most important parts of the automotive engine cooling system. Its performance directly influences the heat dissipation and dynamic performance of the automotive engine, reliability and even driving safety. With the expansion of global new energy vehicle market, the radiators for new energy vehicles is growing rapidly in both number and market size. According to CRI, in the context of economic globalization and fierce competition in the automotive industry, to minimize production costs and enhance international competitiveness, the world’s major automakers have been…

The post Research Report on Global and China’s Automotive Radiator Industries, 2019-2023 first appeared on CRI Report.

]]> Description
The automotive radiator is one of the most important parts of the automotive engine cooling system. Its performance directly influences the heat dissipation and dynamic performance of the automotive engine, reliability and even driving safety. With the expansion of global new energy vehicle market, the radiators for new energy vehicles is growing rapidly in both number and market size.
According to CRI, in the context of economic globalization and fierce competition in the automotive industry, to minimize production costs and enhance international competitiveness, the world’s major automakers have been accustomed to purchase parts worldwide. Since China joined the WTO, China’s automotive radiator industry has been growing rapidly. On one hand, the steady growth of global automotive parts market promotes the export of China-made automotive radiators. On the other hand, the fast development of China’s automotive industry boosts the demand for automotive radiators. China had been the world’s largest automobile producer and seller for nine consecutive years from 2009 to 2018. The production volume of automobiles in China was only 13.79 million units in 2009 while it reached about 27.81 million units in 2018; the automobile reserves in China were less than 80 million units at the end of 2009 while it reached 240 million units in 2018, which showed exponential growth.
Although both global and domestic automobile production shrank in 2018, global automobile reserves are rising, and global automotive radiator market are expanding.
According to CRI, in 2018, the production volume of automotive radiators in China was about 62.81 million units, about 23 million units of which were exported. China’s automotive radiator market is fiercely competitive, with at least 500 manufacturers. However, most of the automotive radiator manufacturers in China are small-sized enterprises. High certification requirements shut most domestic automotive radiator manufacturers out of the OEM market. The target markets of most Chinese automotive radiator manufacturers are domestic and overseas aftermarkets.
The main raw materials for automotive radiators are metals such as copper and aluminum. The price and performance of raw materials have a large impact on the quality, manufacturing costs and performance of automotive radiators. From 2016 to 2019, the prices of aluminum and cooper fluctuate in China. To hedge the risks from volatile raw material prices, large automotive parts manufacturers tend to sign long-term cooperation agreements with suppliers.
CRI expects that from 2019 to 2023, global and China’s automobile reserves will keep increasing and the production and sales volumes of automobiles will also rise. The increasing automobile production will drive the demand for automotive radiators on the OEM market. And global car owners’ demand for automobile maintenance will promote the development of automotive radiators on the aftermarket. As China-made automotive radiators have cost advantages on the global market, the export volume of automotive radiators in China will continue to increase from 2019 to 2023. In addition, global production and reserves of new energy vehicles will certainly increase sharply from 2019 to 2023, and the number and average price of the radiators for new energy vehicles surpass those of the radiators for fuel vehicles, which will boost the growth of global automotive radiator market.

Topics covered:
– Analysis on development environment for the automotive radiator industry
– Analysis on global and China’s automotive parts industries
– Supply of and demand for automotive parts
– Costs of automotive radiator production
– Analysis on export of automotive radiators in China
– Price trends of raw materials for automotive radiators
– Major automotive radiator manufacturers in China and other parts of the world
– Driving forces and market opportunities for the automotive radiator industry from 2019 to 2023
– Threats and challenges to the automotive radiator industry from 2019 to 2023
– Prospect of the automotive radiator industry from 2019 to 2023

The post Research Report on Global and China’s Automotive Radiator Industries, 2019-2023 first appeared on CRI Report.

]]> Research Report on China’s Boiler Industry, 2019-2023 https://www.cri-report.com/research-report-on-chinas-boiler-industry-2019-2023/ Tue, 20 Aug 2019 01:17:39 +0000 https://www.cri-report.com/product/import-placeholder-for-1908395/ Description Boilers play an important role in China’s economy and Chinese people’s lives. The boiler is one of the major equipment of thermal power generation. By the end of 2018, the installed thermal power capacity in China was about 1.14 billion kilowatts, accounting for 60% of the total installed capacity of electricity in China. And it is still rising. According to CRI, by the end of 2018, there were more than 500 boiler manufacturers in China, and the average annual production volume was less than 1,000 evaporation tons. China’s boiler…

The post Research Report on China’s Boiler Industry, 2019-2023 first appeared on CRI Report.

]]> Description
Boilers play an important role in China’s economy and Chinese people’s lives. The boiler is one of the major equipment of thermal power generation. By the end of 2018, the installed thermal power capacity in China was about 1.14 billion kilowatts, accounting for 60% of the total installed capacity of electricity in China. And it is still rising.
According to CRI, by the end of 2018, there were more than 500 boiler manufacturers in China, and the average annual production volume was less than 1,000 evaporation tons. China’s boiler industry is troubled by low market concentration ratio, outdated technologies and low gross profit margins.
China-made boilers are dominated by industrial boilers. In industrial production, industrial boilers are essential thermal power equipment. They are classified into coal-fired steam boilers, oil and gas fired steam boilers, thermal oil furnaces, hot-blast stoves and applied in power generation, industrial production, light industry, textiles, metallurgy, etc.
As coal-fired boilers cost much less than natural gas boilers, they dominate China’s industrial boiler market. For a long time to come, they will continue to be the mainstream of industrial boilers in China, and most of them will be medium and heavy-duty ones. Coal-fired boilers cause serious environmental pollution. As the energy supply structure changes and energy conservation and environmental protection requirements become more stringent, small coal-fired industrial boilers will be phased out, and the energy-efficient and low-pollution industrial boilers that use clean fuels and clean combustion technologies will become a development trend.
As China’s environmental protection policies become stricter, in recent years, the Chinese government is promoting the transformation and upgrade of industrial boiler manufacturers. In Jul. 2016, China’s Ministry of Industry and Information Technology issued the Plan for Industrial Application of Energy Efficient and Environmentally Friendly Industrial Boilers to transform and upgrade the industrial boiler industry, save energy, reduce emissions and improving the environment. The Plan requires that by the end of 2020, some production bases of energy efficient and environmentally friendly industrial boilers should have been built, and energy efficient and environmentally friendly industrial boilers should take up a market share of more than 60% with a production volume of 1 million evaporation tons.
Many local governments of China have also taken measures to control the pollutant discharge of industrial enterprises. Replacing coal-fired boilers with natural gas boilers or electric boilers has become a hot trend. In cities which have the pipelines for the West-East Gas Transmission Project and natural gas import and port cities that are able to import liquefied gas and their surrounding areas, gas-fired boilers have huge growth potential. Supported and encouraged by the Chinese government, the gas-fired boiler industry has a bright prospect.
To meet the standards on energy conservation and environmental protection, many industrial boiler manufacturers are upgrading their boilers. Supported and encouraged by the Chinese government, the gas-fired boiler industry will have a bright prospect. Environmentally friendly gas-fired boilers will certainly replace coal-fired boilers to become the mainstream products on China’s boiler market.

Topics covered:
– Status of China’s boiler industry
– Chinese government’s policies on the boiler industry
– Progress in the replacement of coal-fired boilers with gas-fired boilers
– Competition in China’s boiler industry
– Major boiler manufacturers in China
– Major factors influencing the development of China’s boiler industry
– Prospect of China’s boiler industry

The post Research Report on China’s Boiler Industry, 2019-2023 first appeared on CRI Report.

]]> Research Report on Global and China’s Valve Industries, 2019-2023 https://www.cri-report.com/research-report-on-global-and-chinas-valve-industries-2019-2023/ Tue, 20 Aug 2019 01:17:36 +0000 https://www.cri-report.com/product/import-placeholder-for-1908394/ Description A valve is a device that regulates, directs or controls the flow of fluid by opening, closing, or partially obstructing various passageways. A Valve is a key device in fluid controlling system, which is generally applied in liquid or gaseous fluid controlling environment. The major application fields include petroleum, natural gas, electric power, chemical industry, water supply and sewage treatment, papermaking, metallurgy, pharmacy and food producing. The development of the valve industry is closely related to global economy because valves are widely applied to industries that involve fluid controlling.…

The post Research Report on Global and China’s Valve Industries, 2019-2023 first appeared on CRI Report.

]]> Description
A valve is a device that regulates, directs or controls the flow of fluid by opening, closing, or partially obstructing various passageways. A Valve is a key device in fluid controlling system, which is generally applied in liquid or gaseous fluid controlling environment. The major application fields include petroleum, natural gas, electric power, chemical industry, water supply and sewage treatment, papermaking, metallurgy, pharmacy and food producing. The development of the valve industry is closely related to global economy because valves are widely applied to industries that involve fluid controlling.
According to CRI, in 2018, the global market size of valves was about USD 55 billion, representing a CAGR of about 3.50% from 2014 to 2018. Global leading valve manufacturers are concentrated in North America, Japan and Germany. Famous valve enterprises include Emerson, IMI, Kitz Group, Flowserve, GE, Cameron and KSB Group. They dominate the market through advanced technologies and worldwide manufacturing bases. Global valve market is fiercely competitive and is becoming increasingly concentrated because of mergers and reorganizations. To reduce costs, many world-famous valve manufacturers are closing down their factories in North America, Europe and Japan and moving to China, India, Southeast Asia, etc.
Since China joined the WTO, its valve industry has been developing rapidly. China has the largest number of valve manufacturers and the largest volume of valve production. Currently, about 50% global valve parts are purchased from China. More finished valve products are purchased from China considering factors like OEM. China has become the largest valve exporter in the world, but it still needs to import a large quantity of medium-high end valves every year.
According to CRI, there are over 1,000 valve manufacturers in China. Zhejiang is the largest and leading pump valve manufacturing base and sales center in China. Most of the valve enterprises in Zhejiang are small-sized ones, of which less than 500 have annual sales revenue above CNY 20 million and less than 50 have annual sales revenue above CNY 100 billion. China’s valve market is fragmented, with CR10 below 10%.
According to CRI, in 2018, the production volume of valves in China was about 7.70 million tons, decreasing by about 2% YOY. Although the production volume is declining, the average price is increasing because the proportion of low-end products is decreasing. In recent years, the major driving forces for China’s valve market are industries such as central-air conditioning, energy, electric power and metallurgy.
For example, the market size of central air-conditioning in China exceeded CNY 90 billion in 2018. And as the Chinese government increases the investment in nuclear power, the installed nuclear power capacity is expected to reach 75 million kilowatts at the end of 2020. A 1-million-kilowatt nuclear power project needs refrigeration equipment worth about CNY 150 million to CNY 200 million. In the coming decade, the market size of refrigeration equipment for nuclear power projects will exceed CNY 10 billion. Meanwhile, with the increasing fixed-asset investment, big projects such as the West-to-East Gas Piping Project and the South-to-North Water Diversion Project will need a large quantity of valves. In addition, with the advent of industrial automation, there is an increasing demand for valves from the petrochemical industry, electric power sector, metallurgy sector, chemical industry and urban construction.
According to CRI, the global economy is expected to grow in the next few years, which will push up fixed-asset investment and boost the valve market. As China accelerates urbanization, industrialization and infrastructure construction, fixed-asset investment will remain a major driving force for China’s economic development for a long period of time. And the development of electric power, chemical industry, metallurgy, papermaking and water treatment will stimulate the demand for valves in China. The Chinese government’s policies on promoting economic growth will also drive the development on China’s valve industry.

Topics covered:
– Development environment for global and China’s valve industries
– Supply of and demand for valves
– Analysis on major valve manufacturers in the world
– Competition on the valve market
– Import and export of valves in China
– Driving forces and market opportunities for the valve industry
– Threats and challenges to global valve industry
– Prospect of global valve industry from 2019 to 2023

The post Research Report on Global and China’s Valve Industries, 2019-2023 first appeared on CRI Report.

]]>